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Cardiac arrhythmias during dobutamine infusion
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p 0.01 0.001 0.112 0.018 0.015 0.127
Table 1. Some characteristics of HF patients
Age (mean) 61.7011.75
Gender (m/f) 30 / 17
BMI 28.07
HT 21 (%44.7)
HLP 35 (%74.5)
DM 29 (%61.7)
LVEF (all HF group's average) %30.4010.4
SVEF (LVD group) %26.667.19
PEF-KY (n) 8 (%17)
DEF-KY (n) 39 (%83)
HF: Heart failure, BMI: body mass index, HT: hypertension, HLP: hyperlipidemia, DM: diabetes
mellitus LVEF: left ventricle ejection fraction LVD: left ventricle dysfunction, PEF: preserved
ejection fraction LEF: low ejection fraction
Table 2. miRNA expression fold changes
According to the normal
at admission
According to the normal
at discharge
miR- 22 - 2.39 f - 1.23 f
miR- 24 - 2.07 f - 1.59 f
miR- 92b + 2.33 f + 3.0 f
miRNA (miR): microribonucleic acid
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Introductıon: The new generation continuous-ﬂow left ventricle assist devices
(LVAD) is an option for heart transplantation for end-stage heart failure. These kind of
devices which developped with new technology, are implanted widely all over the
world for bridge to transplantation as well as destination therapy. The effect of LVAD
therapy on pulmonary artery pressure (PAP) in patients with ﬁxed pulmonary artery
hypertension (PAH) who are not good candidate for heart transplant, is an important
research topic. In this study, we evaluated the course of PAP in LVAD therapy and its
effect to post-transplant results.
Materıals-Methods: Between December 2008 and June 2013, continuous-ﬂow-
LVAD implantation were performed in 73 patients. Mean age was 48.39 years and
87% was male. The common etiology for heart failure was Idiopathic dilated
cardiomyopathy (69%). 9 of 73 patients (12,3%) were succesfully bridged to trans-
plantation. 8 patients with ﬁxed PAH were included in this study. PAP levels were
retrospectively compared before LVAD, after LVAD and after heart transplantion.
Results: Mean PAP before LVAD,after LVAD therapy and after heart transplant was
respectively 59,6 mmHg,34.8mmHg and 32.8mmHg. The reduction of PAP was
evident in patients supported with LVAD more than 60 days and consequently
complications related to PAH were lower in this group. Two patients were died in
early period of after heart transplant, the common feature of them was short support
time after LVAD. Mean support time was 34 days. PAP was still high after LVAD and
the main cause of mortality was right heart failure related multi-organ failure.
Conclusıon: The study is limited due to low-number of patients. But the decline of
ﬁxed PAH even it is refractory to vasodilator therapy was found in our analysis. As
a conclusion we think that LVAD therapy before heart transplantation, in patients
with decompansated heart failure and severe PAH, improves the results of heart
transplantation.
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Aim: The relationship of miRNA levels in patients admitted to the hospital because of
acute decompensated heart failure (ADHF) as cause of heart failure, in hospital and
short-term cardiovascular events, hospital readmission and mortality.
Method: Our study included 47 patients with decompansated HF (10 non-ischemic
and 37 ishemic origin) and 30 healty subjects (mean age: 57.138.32, %46.6 men).
Peripheral blood was withdrawn and kept under appropriate circumstances to evaluate
miR-22, miR-24 and miR-92b levels. When sample collection was completed, the
levels of mRNA detected from peripheral blood cells (leukocytes) were calculated
using the method PCR. The fold differences between groups were calculated as
average and miRNA6Ct(the amount of normalized miRNA in a cycle) values were
used for comparison.JACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POSTResults: %63.8 of the patients were male and mean age was 61.7011.75. 39 patient
had left ventricular systolic dysfunction and the average LVEF was %26.667.19. All
patients', in-hospital mortality was %6.3, 1-month mortality rate was %4.5 and in this
duration hospital readmission rate was %31.8. There was a signiﬁcant fold change (>2
fold) between the patients miR-22, miR-24 and miR-92b levels and the control group.
However, the signiﬁcant changes in miRNA, both in low and preserved left ventricular
systolic function or in terms of etiology of HF showed no difference. Similarly, there
was no correlation between the6Ct values in terms of in-hospital and short-term
cardiovascular endpoints.
Conclusıon: Although there was a signiﬁcant fold change in miRNA levels in
patients hospitalized for ADHF, it did not correlate with the clinical endpoints ana-
lysed with6Ct values.PP-066
The Relationship between Heart Failure Stage/Symptom Class and Anxiety
Etem Çelik1, Serkan Çay1, Sani Murat2, Fatih Öksüz1, Tayyar Cankurt1,
Mehmet Ali Mendi1
1Turkiye Yuksek Ihtisas Hospital, Ankara, 2Ankara Training Hospital, Ankara
Background: Anxiety disorders are most common encountered psychiatric disorders.
There is no data regarding the relationship between this widely seen situation and
heart failure stage/symptom class.
Aim: The aim of this study is to evaluate the relationship between various stages of
anxiety disorders and heart failure stages/symptom classes.
Methods: A total of consecutive 419 patients with a mean age of 57.914.4 years
(age range, 18-96 years) admitted with the symptoms of heart failure and/or with risk
factors for heart failure were included in the study. Beck's anxiety inventory including
21 evaluation sentences was applied to all study participants to measure the level and
severity of anxiety symptoms of persons. Measured total scores were used to grade the
severity as minimal, mild, moderate, and severe.
Results: Two hundred and nineteen patients (52.3%) were male, 247 (58.9%) had
hypertension, 139 (33.2%) had diabetes, and 248 cases (59.2%) had coronary heart
disease. Stage A heart failure was present in 113 patients (27.0%), stage B in 119
patients (28.4%), stage C in 116 patients (27.7%), and stage D in remaining 71 cases
(16.9%). With regard to NYHA classiﬁcation, 228 patients (54.4%) had class I
symptoms, 101 (24.1%) had class II symptoms, 31 (7.4%) had class III symptoms, and
class IV symptoms were found in remaining 59 patients (14.1%). The mean left
ventricular ejection fraction of all population was 54.2%  12.4 and the mean Beck's
anxiety score was 13.49.0. Neither heart failure stages nor symptom classes were
found to be statistically different among 4 study groups regarding anxiety scores and
severity (all p>0.05) (table).
Conclusıon: There was no association between heart failure stage/class and anxiety
score/severity in a wide population of heart failure patients.ERS C107
